Xeljanz Reduces Spinal Inflammation in One-third of AS Patients, Phase 2 Trial Shows

Treatment with Xeljanz (tofacitinib citrate) led to a clinically meaningful reduction in spinal and sacroiliac joint inflammation in approximately one-third of ankylosing spondylitis (AS) patients taking part in a Phase 2 clinical trial. The study, “Tofacitinib is associated with attainment of the minimally important…